Enavogliflozin for heart health in obesity and diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests if Enavogliflozin, a medication for diabetes, can improve blood flow in the small vessels of the heart and overall heart function in people with obesity or diabetes. You may join if you have obesity or diabetes and have had a recent heart test.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 79 years old.
- You have obesity (BMI 25 or higher) or a large waistline (men 90 cm, women 85 cm), or you have diabetes (A1c 6.5% or higher, high fasting blood sugar, or on diabetes medication).
- You have had a test called coronary flow velocity reserve (a type of heart ultrasound) in the past.
- You are not taking any other SGLT2 inhibitor diabetes drugs (like dapagliflozin or empagliflozin) and have not taken them in the last 6 months.
- You do not have certain heart problems (like heart failure, blockages, or irregular rhythms), kidney failure, lung disease, active cancer, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called enavogliflozin (an SGLT2 inhibitor) to see if it helps people with a specific type of heart failure where the heart pumps normally but is stiff. You may be able to join if you have stable heart failure, are not on another SGLT2 inhibitor, and have good kidney function.
This study tests a drug called enavogliflozin to see if it helps people with a specific type of heart failure caused by amyloid buildup. It may improve symptoms and daily function.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This trial tests enavogliflozin (a diabetes medication that may help the heart) in people who have had a TAVR procedure for severe aortic stenosis. It looks at whether the medicine can improve outcomes for people with symptoms and mildly reduced or preserved pumping function.
This study looks at how well a medication called Enavogliflozin works for people with type 2 diabetes who also have high blood pressure or high cholesterol. It aims to see if the drug is safe and effective when taken as part of routine care.
Hear when a new Obesity and Type 2 Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.